Fever is a common clinical symptom, often indicative of an underlying pathological condition. As healthcare professionals, it is crucial to understand the mechanisms, evaluation, and management strategies of fever.
Fevers are typically a result of the body's immune response to infection or inflammation. Pyrogens stimulate the hypothalamus to increase the body's set point temperature, leading to fever. It's important to note, however, that non-infectious diseases, certain drugs, and malignancies can also trigger a febrile response.
A thorough history and physical examination are essential in fever evaluation. Key aspects include travel history, exposure to infectious diseases, medication history, and presence of immunosuppression. Laboratory investigations, including complete blood count, cultures, and inflammatory markers, can provide valuable insights.
Management primarily focuses on treating the underlying cause. Antipyretics, like acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), can be used for symptomatic relief. However, their use should be judicious, as fever plays a crucial role in host defense mechanisms. In cases of persistently high fever or febrile patients with significant comorbidities, hospitalization may be necessary.
Children and immunocompromised individuals require special attention, as fever might indicate a severe infection. In neonates, even a slight elevation in temperature warrants immediate evaluation. Similarly, in immunocompromised patients, fever could be the only sign of a potentially life-threatening infection.
Managing fever in clinical practice requires a comprehensive understanding of its mechanisms, evaluation techniques, and appropriate management strategies. By adopting a systematic approach, healthcare professionals can ensure effective patient care and optimize outcomes.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation